Published on
03:46 GMT
Korean regulator releases post-marketing survey results on GSK’s Trelegy adverse reactions
GSK’s Trelegy medicines for asthma and chronic obstructive pulmonary disease (COPD) have been linked to adverse reactions in 11.36 percent of asthma patients and 38.61 percent of COPD patients in a post-marketing surveillance (PMS) study in Korea, the …
Source:
Korea Biomedical Review
-
Neutral
